|
1.
|
Ron D: Translational control in the
endoplasmic reticulum stress response. J Clin Invest.
110:1383–1388. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Szegezdi E, Logue SE, Gorman AM and Samali
A: Mediators of endoplasmic reticulum stress-induced apoptosis.
EMBO Rep. 7:880–885. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Hamamura K and Yokota H: Stress to
endoplasmic reticulum of mouse osteoblasts induces apoptosis and
transcriptional activation for bone remodeling. FEBS Lett.
581:1769–1774. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Hamamura K, Goldring MB and Yokota H:
Involvement of p38 MAPK in regulation of MMP13 mRNA in chondrocytes
in response to surviving stress to endoplasmic reticulum. Arch Oral
Biol. 54:279–286. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Boyce M, Bryant KF, Jousse C, et al: A
selective inhibitor of eIF2α dephosphorylation protects cells from
ER stress. Science. 307:935–939. 2005.
|
|
6.
|
Liu CL, Li X, Hu GL, et al: Salubrinal
protects against tunic-amycin and hypoxia induced cardiomyocyte
apoptosis via the PERK-eIF2α signaling pathway. J Geriatr Cardiol.
9:258–268. 2012.PubMed/NCBI
|
|
7.
|
Drexler HCA: Synergistic apoptosis
induction in leukemic cells by the phosphatase inhibitor salubrinal
and proteasome inhibitors. PLoS One. 4:e41612009. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Koizumi M, Tanjung NG, Chen A, et al:
Administration of salubrinal enhances radiation induced cell death
of SW1353 chondrosarcoma cells. Anticancer Res. 32:3667–3674.
2012.PubMed/NCBI
|
|
9.
|
Osborne CK, Zhao H and Fuqua SA: Selective
estrogen receptor modulators: structure, function, and clinical
use. J Clin Oncol. 18:3172–3186. 2000.PubMed/NCBI
|
|
10.
|
De Laurentiis M, Cianniello D, Caputo R,
et al: Treatment of triple negative breast cancer (TNBC): current
options and future perspectives. Cancer Treat Rev. 36(Suppl 3):
S80–S86. 2010.
|
|
11.
|
Gluz O, Liedtke C, Gottschalk N, Pusztai
L, Nitz U and Harbeck N: Triple-negative breast cancer-current
status and future directions. Ann Oncol. 20:1913–1927. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Bosch A, Eroles P, Zaragoza R, Vina JR and
Lluch A: Triple-negative breast cancer: molecular features,
pathogenesis, treatment and current lines of research. Cancer Treat
Rev. 36:206–215. 2010. View Article : Google Scholar
|
|
13.
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Prud’homme GJ, Glinka Y, Toulina A, Ace O,
Subramaniam V and Jothy S: Breast cancer stem-like cells are
inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS
One. 5:e138312010.PubMed/NCBI
|
|
15.
|
Bouquet F, Pal A, Pilones KA, et al: TGFβ1
inhibition increases the radiosensitivity of breast cancer cells in
vitro and promotes tumor control by radiation in vivo. Clin Cancer
Res. 17:6754–6765. 2011.
|
|
16.
|
Kaur P, Nagaraja GM, Zheng H, et al: A
mouse model for triple-negative breast cancer tumor-initiating
cells (TNBC-TICs) exhibits similar aggressive phenotype to the
human disease. BMC Cancer. 12:1202012. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Tsaytler P, Harding HP, Ron D and
Bertolotti A: Selective inhibition of a regulatory subunit of
protein phosphatase 1 restores proteostasis. Science. 332:91–94.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Niknejad N, Gorn-Hondermann I, Ma L, et
al: Lovastatin-induced apoptosis is mediated by activating
transcription factor 3 and enhanced in combination with salubrinal.
Int J Cancer. 134:268–279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Hamamura K, Furukawa K, Hayashi T, et al:
Ganglioside GD3 promotes cell growth and invasion through p130Cas
and paxillin in malignant melanoma cells. Proc Natl Acd Sci USA.
102:11041–11046. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Shibuya H, Hamamura K, Hotta H, et al:
Enhancement of malignant properties of human osteosarcoma cells
with disialyl gangliosides GD2/GD3. Cancer Sci. 103:1656–1664.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Sander EE and Collard JG: Rho-like
GTPases: Their role in epithelial cell-cell adhesion and invasion.
Eur J Cancer. 35:1302–1308. 1999. View Article : Google Scholar
|
|
22.
|
Wertheimer E, Gutierrez-Uzquiza A,
Rosemblit C, Lopez-Haber C, Sosa MS and Kazanietz MG: Rac signaling
in breast cancer: a tale of GEFs and GAPs. Cell Signal. 24:353–362.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Heid I, Lubeseder-Martellato C, Sipos B,
et al: Early requirement of Rac1 in a mouse model of pancreatic
cancer. Gastroenterology. 141:719–730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Welch HCE, Coadwell WJ, Ellson CD,
Ferguson GJ, Andrews SR, Erdjument-Bromage H, et al: P-Rex1, a
Ptdlns (3,4,5)P3- and Gβγ-regulated guanine-nucleotide exchange
factor for Rac. Cell. 108:809–821. 2002.
|
|
25.
|
Yoshizawa M, Kawauchi T, Sone M, et al:
Involvement of a Rac activator, p-Rex1, in neurotrophin-derived
signaling and neuronal migration. J Neurosci. 25:4406–4419. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Shim JW, Hamamura K, Chen A, Wan Q, Na S
and Yokota H: Rac1 mediates load-driven attenuation of mRNA
expression of nerve growth factor beta in cartilage and
chondrocytes. J Musculoskelet Neuronal Interact. 13:372–379.
2013.PubMed/NCBI
|
|
27.
|
Rosenblatt AE, Garcia MI, Lyons L, et al:
Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor
levels and is a novel therapeutic strategy in breast cancer. Endocr
Relat Cancer. 18:207–219. 2011.
|
|
28.
|
Yang Y, Du J, Hu Z, et al: Activation of
Rac1-PI3K/Akt is required for epidermal growth factor-induced PAK1
activfation and cell migration in MDA-MB-231 brest cancer cells. J
Biomed Res. 25:237–245. 2011. View Article : Google Scholar
|
|
29.
|
Eckhardt BL, Francis PA, Parker BS and
Anderson RL: Strategies for the discovery and development of
therapies for metastatic breast cancer. Nat Rev Drug Discov.
11:479–497. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Van Poznak CH, Temin S, Yee GC, et al:
American society of clinical oncology executive summary of the
clinical practice guideline update on the role of bone-modifying
agents in meta-static breast cancer. J Clin Oncol. 29:1221–1227.
2011.PubMed/NCBI
|
|
31.
|
Lee BL, Higgins MJ and Goss PE: Denosumab
and the current status of bone-modifying drugs in breast cancer.
Acta Oncol. 51:157–167. 2012. View Article : Google Scholar
|
|
32.
|
Marx RE: Pamidronate (Aredia) and
zoledronate (Zometa) induced avascular necrosis of the jaws: a
growing epidemic. J Oral Maxillofac Sug. 61:1115–1118. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
He L, Lee J, Jang JH, et al: Osteoporosis
regulation by salubrinal through eIF2α mediated differentiation of
osteoclast and osteoblast. Cell Signal. 25:552–560. 2013.
|
|
34.
|
Hamamura K, Tanjung N and Yokota H:
Suppression of osteoclastogenesis through phosphorylation of
eukaryotic translation initiation factor 2 alpha. J Bone Miner
Metab. 31:618–628. 2013. View Article : Google Scholar : PubMed/NCBI
|
